The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Sponsor
Karl Neff
Study ID
NCT01847313
Phase
PHASE3
Status
Completed

Conditions

  • Diabetic Kidney Disease

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Daily administration of liraglutide for 6 months

Study Details

Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure. A group of medicines used to treat diabetes, glucagon-like-peptide-1 analogues (GLP-1), may be able to protect people with diabetes from DKD by reducing inflammation in the kidney. This study aims to test this theory by studying the effect of GLP-1 on kidney function in people with diabetes. To understand how GLP-1 can affect inflammation, the investigators will give a GLP-1 treatment (Liraglutide) to people with DKD and monitor the effect on inflammation and kidney function using blood and urine tests. The investigators will compare these results to patients with DKD who do not receive GLP-1 treatment. If GLP-1 proves to be effective in reducing inflammation and improving kidney function, then it could be developed as a viable new treatment for people with DKD, and may significantly reduce the disease burden, or the risk of DKD, in people with diabetes. This would be a major advance in the treatment of DKD.

Key Dates

Start date
Apr 30, 2013
Status verified
Sep 2018
Primary completion
Nov 30, 2015
Completion
Nov 30, 2015

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide
    Liraglutide 0.6 mg daily
  • No Intervention: Control
    Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist

Primary Outcome Measure

MCP-1:Creatinine Ratio in Urine [ Time Frame: Up to 26 weeks ]

Related Studies